# A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

> **NCT02069119** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** OPC-108459
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02069119
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069119, "A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02069119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*